A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

PHASE2CompletedINTERVENTIONAL
Enrollment

381

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

November 28, 2022

Study Completion Date

November 28, 2022

Conditions
HypercholesterolemiaFamilial Hypercholesterolemia
Interventions
DRUG

Enclitide Chloride

Enclitide Chloride administered orally

DRUG

Placebo

Placebo matching enclitide chloride administered orally

Trial Locations (63)

1478

Akershus Universitetssykehus-Hjertemedisinsk Avdeling ( Site 0705), Lørenskog

3103

Sykehuset i Vestfold-Hjerteseksjonen ( Site 0703), Tønsberg

4011

Stavanger Universitetssykehus ( Site 0706), Stavanger

8005

Nordlandssykehuset ( Site 0709), Bodø

11410

Bio Investigación AMARC, S.C. ( Site 0204), Mexico City

11850

Hospital Angeles Mocel ( Site 0209), Mexico City

12553

Mid Hudson Medical Research ( Site 0004), New Windsor

13353

Charité Campus Virchow-Klinikum ( Site 0505), Berlin

14080

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0212), Mexico City

16635

altoona center for clinical research ( Site 0045), Duncansville

20129

Centro de Atención e Investigación Clínica ( Site 0214), Aguascalientes

23294

National Clinical Research, Inc-research office ( Site 0019), Richmond

26480

Eskisehir Osmangazi University-Cardiology ( Site 1000), Eskişehir

29707

Piedmont Research Partners ( Site 0005), Fort Mill

33134

Alliance for Multispecialty Research, LLC ( Site 0050), Coral Gables

33434

Excel Medical Clinical Trials ( Site 0042), Boca Raton

33613

ForCare Clinical Research ( Site 0017), Tampa

34121

Ambulantes Herzzentrum Kassel ( Site 0501), Kassel

35100

Ege University Medicine of Faculty-Cardilogy Department ( Site 1003), Bornova

39216

The University of Mississippi Medical Center-Clinical Research and Trials Unit ( Site 0028), Jackson

40213

L-MARC Research Center ( Site 0003), Louisville

42601

Keimyung University Dongsan Hospital ( Site 1703), Daegu

44150

Unidad de Investigaci�n Cl�nica Cardiometabolica de Occident-Unidad de Investigación Clínica Cardio, Guadalajara

46260

Midwest Institute For Clinical Research ( Site 0036), Indianapolis

60422

Healthcare Research Network - Chicago ( Site 0037), Flossmoor

64460

Unidad biomedica avanzada monterrey-Clinical Trials ( Site 0200), Monterrey

66606

Cotton O'Neil Mulvane ( Site 0022), Topeka

75230

Dallas Diabetes Research Center ( Site 0012), Dallas

77030

Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0051), Houston

78233

Northeast Clinical Research of San Antonio ( Site 0014), San Antonio

80336

Klinikum der Ludwig-Maximilians-Universitaet Muenchen ( Site 0504), München

87106

New Mexico Clinical Research & Osteoporosis Center ( Site 0032), Albuquerque

89106

Jubilee Clinical Research ( Site 0047), Las Vegas

89440

Centro de Estudios de Investigacion Metabolicos y Cardiovasculares-Subinvestigation ( Site 0201), Ciudad Madero

90211

Westside Medical Associates of Los Angeles ( Site 0026), Beverly Hills

90402

Kardiologische Gemeinschaftspraxis ( Site 0502), Nuremberg

91193

Hospital Angeles Xalapa-Internal Medicine-Cardiology ( Site 0202), Xalapa

92704

National Research Institute (NRI) - Santa Ana ( Site 0024), Santa Ana

95821

Clinical Trials Research ( Site 0007), Sacramento

97070

Medical Care and Research SA de CV ( Site 0211), Mérida

04103

Universitätsklinikum Leipzig ( Site 0500), Leipzig

455-8530

Chubu Rosal Hospital ( Site 1612), Nagoya

613-0034

Kyoto Okamoto Memorial Hospital ( Site 1611), Kuse-gun Kumiyama-cho

538-0044

Kitada Clinic ( Site 1604), Osaka

565-0853

Medical Corporation Heishinkai OCROM Clinic ( Site 1600), Suita-shi

123-0845

Seiwa Clinic ( Site 1605), Adachi-ku

101-0041

meiwa hospital ( Site 1602), Chiyoda-ku

160-0008

Heishinkai Medical Group ToCROM Clinic ( Site 1601), Shinjuku-ku

171-0014

Sekino Hospital ( Site 1603), Toshimaku

04460

Instituto Jalisciense de Investigacion en Diabetes y Obesidad-Endocrinology ( Site 0205), Guadalajara

0316

Oslo Universitetssykehus Aker-Preventiv kardiologi Aker ( Site 0704), Oslo

0372

Oslo Universitetssykehus Rikshospitalet-Kardiologisk avdeling ( Site 0702), Oslo

0450

Oslo Universitetssykehus Ullevål-Hjertemedisinsk avdeling, Ullevål ( Site 0701), Oslo

0586

Oslo Universitetssykehus Aker-Lipidklinikken ( Site 0700), Oslo

03080

Seoul National University Hospital ( Site 1702), Seoul

03722

Severance Hospital, Yonsei University Health System ( Site 1701), Seoul

06351

Samsung Medical Center ( Site 1700), Seoul

06230

Hacettepe Universitesi ( Site 1002), Ankara

NW32QG

Royal Free Hospital ( Site 1311), London

G51 4TF

Queen Elizabeth University Hospital-Glasgow Clinical Research Facility ( Site 1310), Glasgow

FY3 7EN

Layton Medical Centre ( Site 1303), Blackpool

EC1M 5PZ

William Harvey Heart Centre ( Site 1308), London

WS2 9PS

Walsall Manor Hospital ( Site 1309), West Midlands

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT05261126 - A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008) | Biotech Hunter | Biotech Hunter